Search

Your search keyword '"Chasnyk, V."' showing total 158 results
Start Over Author "Chasnyk, V."
158 results on '"Chasnyk, V."'

14. POS0748 TOWARD THE DEFINITION OF CUTOFF VALUES FOR DISEASE ACTIVITY STATES IN SYSTEMIC JADAS

Author

Rebollo Giménez, A. I., primary, Vyzhga, Y., additional, Carlini, L., additional, Rosina, S., additional, Patrone, E., additional, Katsikas, M., additional, Saad-Magalhaes, C., additional, El-Ghoneimy, D., additional, El Miedany, Y., additional, Khubchandani, R., additional, Pal, P., additional, Simonini, G., additional, Filocamo, G., additional, Gattinara, M., additional, De Benedetti, F., additional, Montin, D., additional, Civino, A., additional, Alsuweiti, M. O., additional, Stanevicha, V., additional, Chasnyk, V., additional, Alexeeva, E., additional, Al-Mayouf, S., additional, Vilaiyuk, S., additional, and Ravelli, A., additional

Published
2023
Full Text
View/download PDF

16. The experience of rituximab therapy in patients with juvenile systemic lupus erythematosus: the preliminary results of two-center cohort study

Author

Kalashnikova, E. M., primary, Raupov, R. K., additional, Lyubimova, N. A., additional, Kuchinskaya, E. M., additional, Masalova, V. V., additional, Isupova, E. A., additional, Gaidar, E. V., additional, Dubko, M. F., additional, Snegireva, L. S., additional, Sorokina, L. S., additional, Kornishina, T. L., additional, Kaneva, M. A., additional, Chikova, I. A., additional, Likhacheva, T. S., additional, Kolobova, O. L., additional, Kalashnikova, O. V., additional, Chasnyk, V. G., additional, and Kostik, M. M., additional

Published
2023
Full Text
View/download PDF

19. Microwave energy attenuators on the basis of aluminum nitride with high level of microwave energy absorption

Author

Chasnyk V. I.

Subjects
volume attenuators, absorption factor of electromagnetic energy, composite, volume electrical resistance, aluminum nitride, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

Results of experimental studies of aluminum nitride based composites with addition of silicon carbide and molybdenum having high microwave absorption are presented. The interconnection between high level of absorption and volume electrical resistance was observed: maximum absorption of 6.5±1,0 dB/mm corresponds to the electrical resistance of (4—5)·105 Ohm·m. Level of absorption of 3.5±0,5 dB/mm is revealed for the dielectric material with electrical conductivity of 1012 Ohm·m. The patterns detected during the study allow to predict the minimum and maximum levels of absorption of microwave energy in the two-phase composites based on aluminum nitride with molybdenum or silicon carbide, based on the measured volume of electrical resistance.

Published
2014
Full Text
View/download PDF

20. Microwave energy attenuators of high thermal conductivity based on AlN and SiC with addition of molybdenum

Author

Chasnyk V. I. and Fesenko I. P.

Subjects
volume attenuators, absorption factor of electromagnetic energy, composite, aluminum nitride, silicium carbide, molybdenum, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

The paper presents the results of experimental studies of thermal conductivity and microwave absorption in aluminum nitride based composites with different percentages of silicium carbide and molybdenum. It is shown that the optimal composition of the studied materials is the composite with 46% of silicium carbide and 4% of molybdenum. This composition reveals high UHF-energy absorption level of 42 dB/cm in the frequency range of 9.5—10.5 GHz and high thermal conductivity of 65 W/(m*K).

Published
2014
Full Text
View/download PDF

21. POS1320 SAFETY AND EFFICACY OF RITUXIMAB IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: THE PRELIMINARY DATA OF RETROSPECTIVE COHORT STUDY

Author

Kalashnikova, E., primary, Raupov, R., additional, Lybimova, N., additional, Kuchinskaya, E., additional, Kalashnikova, O., additional, Chasnyk, V., additional, Kornishina, T., additional, Snegireva, L., additional, Gaidar, E., additional, Masalova, V., additional, Isupova, E., additional, Kaneva, M., additional, Dubko, M., additional, Likhacheva, T., additional, Sorokina, L., additional, and Kostik, M., additional

Published
2022
Full Text
View/download PDF

22. Complex reduction coefficient for a cylindrical electron beam with variable amplitude of the variable current component in the TWT

Author

Chasnyk V. I. and Strocovsky Ya. N.

Subjects
complex reduction coefficient, cylindrical electron beam, variable current component, space charge, TWT, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

The conventional approach to calculating the space charge for the traveling-wave tube (TWT) with phase velocity jumps is to use the same values of the depression coefficient as the ones for homogeneous helical TWTs. However, if the variable component of the exciting current in the expressions for determining the reduction coefficient is changed in amplitude, then the reduction factor is a complex value. Perhaps the neglect of this fact can significantly affect the volume discharge calculated value, and hence the non-synchronization parameter, for those of its values, which are characteristic of the TWT with a phase velocity jump. In this paper, formulas has been obtained for computation of real and imaginary parts of the complex reduction coefficient for a cylindrical electrons beam with exponential variable amplitude of variable current component in the TWT. Influence of complex reduction coefficient on the parameters of the TWT operating in the linear mode is estimated. It is shown that taking into account the imaginary part of the reduction coefficient for linear operation of the TWT makes it possible to change the estimated amount of space charge 1.5 to 2 times, which in its turn has quite a strong effect on the formation of the initial conditions of the nonlinear mode and, subsequently, on the output characteristics of the TWT.

Published
2013

23. Use of high-thermal conductive aluminum nitride based ceramics in vacuum UHF electronic devices

Author

Chasnyk V. I.

Subjects
ceramics, aluminum nitride, dielectric support, helix, TWT, output window, isolator, collector, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

Analysis of properties and characteristics of the alumina, beryllium oxide and aluminum nitride based ceramic materials used in UHF electronic devices has been made. It was shown that the complex of parameters including structural and functional characteristics of the high-thermal conductive aluminum nitride ceramics prevail over all types of alumina ceramics and is not lower than the same characteristics of the beryllium oxide ceramics especially at the temperatures higher than 450 °C. The examples of the prevailing use of the aluminum nitride ceramics inside vacuum UHF-region devices: TWT’s and klystrons.

Published
2013

24. Dielectric characteristics of the high heat-conducting AlN-ceramics in the frequency range of 3—93 GHz

Author

Chasnyk V. I. and Fesenko I. P.

Subjects
ceramic, aluminum nitride, dielectric constant, dielectric loss tangent, relaxation process, polarization, thermal stability, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

The article presents the results of experimental measurements. It is shown that the behavior of the dielectric constant and dielectric loss tangent in the investigated frequency range is due to the lack of relaxation processes in ceramics associated with the orientation polarization and to weak influence of ion and electron polarization.

Published
2013

26. Studies of the ceramic material produced by pressureless sintering from the AlN-Y2O3-(Si-C) powder composition using electron microscopy, Raman spectroscopy and measurements of the thermal conductivity and microwave radiation

Author

Fesenko, I. P., Chasnyk, V. I., Kolomys, O. F., Kaidash, O. M., Davydchuk, N. K., Serbenyuk, T. B., Kuz’menko, E. F., Gadzyra, M. P., Lyeshchuk, O. O., Strel’chuk, V. V., Galyamin, V. B., Tkach, S. V., Fesenko, E. I., Shmegera, P. S., Azima, Yu. I., Recht, H., and Vollstädt, H.

Published
2015
Full Text
View/download PDF

27. Focusing of intensive electron beams in helix TWT with PPM focusing system with nonsinusoidal field

Author

Chasnyk V. I.

Subjects
TWT helical slow-wave system, PPM with non-sinusoidal field, magnetic field parameter, stability region, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

Experimental results on beam transmission of intensive electron beams in high-voltage TWT with PPM focusing system with nonsinusoidal field at great values of magnetic field parameter α are presented. It is shown, that at 1,01,4, which correspond to the second region of stability, conductance is 82% in statics and 75% in dynamics.

Published
2011

28. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

Author

Giancane G1, Swart JF2, Castagnola E3, Groll AH4, Horneff G5, 6, Huppertz HI7, Lovell DJ8, Wolfs T2, Herlin T9, Dolezalova P10, Sanner H11, Susic G13, Sztajnbok F14, Maritsi D15, Constantin T16, Vargova V17, Sawhney S18, Rygg M19, K Oliveira S21, Cattalini M22, Bovis F1, Bagnasco F1, Pistorio A23, Martini A24, Wulffraat N2, Ruperto N25, Paediatric Rheumatology International Trials Organisation (PRINTO). Cuttica R, Garay SM, Brunner J, Emminger W, Appenzeller S, Len C, Saad Magalhaes C, Telcharova-Mihaylovska A, Harjacek M, Jelusic M, Estmann A, Nielsen S, Herrera Mora C, Gervais E, Koné-Paut I, Quartier P, Foeldvari I, Horneff G, Lutz T, Minden K, Tzaribachev N, Trachana M, Tsitsami E, Vougiouka O, Orban I, Harel L, Hashkes P, Uziel Y, Cimaz R, Civino A, Consolini R, D'Angelo G, De Benedetti F, Filocamo G, Fueri E, Gallizzi R, Maggio MC, Magnolia MG, Miniaci A, Montin D, Olivieri A. N., Pastore S, Rigante D, Zulian F, Rumba-Rozenfelde I, Stanevicha V, Panaviene V, Rodriguez Lozano AL, Rubio-Perez N, Vega Cornejo G, Hoppenreijs E, Kamphuis S, Flato B, Nordal EB, Abdwani R, Miraval T, Paz Gastanaga ME, Smolewska E, Ailioaie C, Cochino AV, Laday M, Lazar C, Alexeeva E, Chasnyk V, Keltsev V, Suwairi WMS, Vijatov-Djuric G, Vojinovic J, Arkachaisri T, Koskova E, Avcin T, Ally M, Van Rensburg CJ, Louw I, Lopez JA, Boteanu AL, Calvo Penades I, De Inocencio J, Mesa-Del-Castillo P, Moreno E, Remesal A, Hofer M, Gok F, Ozen S, Ramanan A, Pallotti C, Villa L., Giancane, G1, Swart, Jf2, Castagnola, E3, Groll, Ah4, Horneff, G5, Huppertz, Hi7, Lovell, Dj8, Wolfs, T2, Herlin, T9, Dolezalova, P10, Sanner, H11, Susic, G13, Sztajnbok, F14, Maritsi, D15, Constantin, T16, Vargova, V17, Sawhney, S18, Rygg, M19, K Oliveira, S21, Cattalini, M22, Bovis, F1, Bagnasco, F1, Pistorio, A23, Martini, A24, Wulffraat, N2, Ruperto, N25, Paediatric Rheumatology International Trials Organisation (PRINTO)., Cuttica R, Garay, Sm, Brunner, J, Emminger, W, Appenzeller, S, Len, C, Saad Magalhaes, C, Telcharova-Mihaylovska, A, Harjacek, M, Jelusic, M, Estmann, A, Nielsen, S, Herrera Mora, C, Gervais, E, Koné-Paut, I, Quartier, P, Foeldvari, I, Horneff, G, Lutz, T, Minden, K, Tzaribachev, N, Trachana, M, Tsitsami, E, Vougiouka, O, Orban, I, Harel, L, Hashkes, P, Uziel, Y, Cimaz, R, Civino, A, Consolini, R, D'Angelo, G, De Benedetti, F, Filocamo, G, Fueri, E, Gallizzi, R, Maggio, Mc, Magnolia, Mg, Miniaci, A, Montin, D, Olivieri, A. N., Pastore, S, Rigante, D, Zulian, F, Rumba-Rozenfelde, I, Stanevicha, V, Panaviene, V, Rodriguez Lozano, Al, Rubio-Perez, N, Vega Cornejo, G, Hoppenreijs, E, Kamphuis, S, Flato, B, Nordal, Eb, Abdwani, R, Miraval, T, Paz Gastanaga, Me, Smolewska, E, Ailioaie, C, Cochino, Av, Laday, M, Lazar, C, Alexeeva, E, Chasnyk, V, Keltsev, V, Suwairi, Wm, Vijatov-Djuric, G, Vojinovic, J, Arkachaisri, T, Koskova, E, Avcin, T, Ally, M, Van Rensburg, Cj, Louw, I, Lopez, Ja, Boteanu, Al, Calvo Penades, I, De Inocencio, J, Mesa-Del-Castillo, P, Moreno, E, Remesal, A, Hofer, M, Gok, F, Ozen, S, Ramanan, A, Pallotti, C, Villa, L., Giancane, Gabriella, Swart, Joost F, Castagnola, Elio, Groll, Andreas H, Horneff, Gerd, Huppertz, Hans-Iko, Lovell, Daniel J, Wolfs, Tom, Herlin, Troel, Dolezalova, Pavla, Sanner, Helga, Susic, Gordana, Sztajnbok, Flavio, Maritsi, Despoina, Constantin, Tama, Vargova, Veronika, Sawhney, Sujata, Rygg, Marite, K Oliveira, Sheila, Cattalini, Marco, Bovis, Francesca, Bagnasco, Francesca, Pistorio, Angela, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino, Cuttica, Ruben, Garay, Stella Mari, Brunner, Jurgen, Emminger, Wolfgang, Appenzeller, Simone, Len, Claudio, Saad Magalhaes, Claudia, Telcharova-Mihaylovska, Albena, Harjacek, Miroslav, Jelusic, Marija, Estmann, Anne, Nielsen, Susan, Herrera Mora, Cristina, Gervais, Elisabeth, Koné-Paut, Isabelle, Quartier, Pierre, Foeldvari, Ivan, Lutz, Thoma, Minden, Kirsten, Tzaribachev, Nikolay, Trachana, Maria, Tsitsami, Elena, Vougiouka, Olga, Orban, Ilonka, Harel, Liora, Hashkes, Philip, Uziel, Yosef, Cimaz, Rolando, Civino, Adele, Consolini, Rita, D'Angelo, Gianfranco, De Benedetti, Fabrizio, Filocamo, Giovanni, Fueri, Elena, Gallizzi, Romina, Maggio, Maria Cristina, Magnolia, Maria Greca, Miniaci, Angela, Montin, Davide, Olivieri, Alma Nunzia, Pastore, Serena, Rigante, Donato, Zulian, Francesco, Rumba-Rozenfelde, Ingrida, Stanevicha, Valda, Panaviene, Violeta, Rodriguez Lozano, Ana Luisa, Rubio-Perez, Nadina, Vega Cornejo, Gabriel, Hoppenreijs, Esther, Kamphuis, Sylvia, Flato, Berit, Nordal, Ellen Berit, Abdwani, Reem, Miraval, Tatiana, Paz Gastanaga, Maria Eliana, Smolewska, Elzbieta, Ailioaie, Constantin, Cochino, Alexis-Virgil, Laday, Matilda, Lazar, Calin, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Keltsev, Vladimir, Suwairi, Wafaa Mohammed Saad, Vijatov-Djuric, Gordana, Vojinovic, Jelena, Arkachaisri, Thaschawee, Koskova, Elena, Avcin, Tadej, Ally, Mahmood, Van Rensburg, Christa Janse, Louw, Ingrid, Lopez, Jordi Anton, Boteanu, Alina Lucica, Calvo Penades, Inmaculada, De Inocencio, Jaime, Mesa-Del-Castillo, Pablo, Moreno, Estefania, Remesal, Agustin, Hofer, Michael, Gok, Faysal, Ozen, Seza, Ramanan, Athimalaipet, Pallotti, Chiara, Villa, Luca, and Pediatrics

Subjects
Male, lcsh:Diseases of the musculoskeletal system, Biologic, Paediatrics: 760 [VDP], Artritis infecciosa, MedDRA, Infants malalts, Arthritis, Severity of Illness Index, Hospital patients, Cohort Studies, Pharmacovigilance, 0302 clinical medicine, 030212 general & internal medicine, Registries, Child, Biologics, Immunosuppressive therapy, Infections, Juvenile idiopathic arthritis, Opportunistic, biologics, immunosuppressive therapy, infections, juvenile idiopathic arthritis, opportunistic, Barneleddgikt, 3. Good health, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Antirheumatic Agents, Child, Preschool, Cohort, Pediatric Infectious Disease, Female, Infection, Research Article, medicine.medical_specialty, Tuberculosis, juvenil idiopathic arthritis, Opportunistic Infections, Herpes Zoster, 03 medical and health sciences, Immunocompromised Host, Juvenile idiopathic arthriti, Internal medicine, medicine, Humans, book, 030203 arthritis & rheumatology, Malalts hospitalitzats, Immunosupressió, business.industry, Sick children, medicine.disease, Rheumatology, Arthritis, Juvenile, Infectious arthritis, Pediatri: 760 [VDP], Orthopedic surgery, Opportunistiske infeksjoner, book.journal, lcsh:RC925-935, business, Infeccions oportunistes, Immunosuppression
Abstract

Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching the adjudicated infections with the provisional list of OI. Results: A total of 772 infectious events in 572 eligible patients, of which 335 serious/severe/very severe non-OI and 437 OI (any intensity/severity), according to the provisional list, were retrieved. Six hundred eighty-two of 772 (88.3%) were adjudicated as infections, of them 603/682 (88.4%) as common and 119/682 (17.4%) as OI by the SAC. Matching these 119 opportunistic events with the provisional list, 106 were confirmed by the SAC as OI, and among them infections by herpes viruses were the most frequent (68%), followed by tuberculosis (27.4%). The remaining events were divided in the groups of non-OI and possible/patient and/or pathogen-related OI. Conclusions: We found a significant number of OI in JIA patients on immunosuppressive therapy. The proposed list of OI, created by consensus and validated in the Pharmachild cohort, could facilitate comparison among future pharmacovigilance studies. © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published
2020

30. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study

Author

Quartier P, Alexeeva E, Tamàs C, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton-Lopez J, Wei X, Slade A, Ruperto N, Abrams K, and Pediatric Rheumatology International Trials Organization (PRINTO), the Pediatric

Abstract

OBJECTIVE: To evaluate the efficacy and safety of 2 canakinumab monotherapy tapering regimens in order to maintain complete clinical remission in children with systemic juvenile idiopathic arthritis (JIA). METHODS: The study was designed as a 2-part phase IIIb/IV open-label, randomized trial. In the first part, patients received 4 mg/kg of canakinumab subcutaneously every 4 weeks and discontinued glucocorticoids and/or methotrexate as appropriate. Patients in whom clinical remission was achieved (inactive disease for at least 24 weeks) with canakinumab monotherapy were entered into the second part of the trial, in which they were randomized 1:1 into 1 of 2 treatment arms. In arm 1, the dose of canakinumab was reduced from 4 mg/kg to 2 mg/kg and then to 1 mg/kg, followed by discontinuation. In arm 2, the 4 mg/kg dose interval was prolonged from every 4 weeks, to every 8 weeks, and then to every 12 weeks, followed by discontinuation. In both arms, canakinumab exposure could be reduced provided systemic JIA remained in clinical remission for 24 weeks with each step. The primary objective was to assess whether >40% of randomized patients in either arm maintained clinical remission of systemic JIA for 24 weeks in the first part of the study. RESULTS: In part 1 of the study, 182 patients were enrolled, with 75 of those patients randomized before entering part 2 of the trial. Among the 75 randomized patients, clinical remission was maintained for 24 weeks in 27 (71%) of 38 patients in arm 1 (2 mg/kg every 4 weeks) and 31 (84%) of 37 patients in arm 2 (4 mg/kg every 8 weeks) (P = 0.0001 for arm 1 versus arm 2 among those meeting the 40% threshold). Overall, 25 (33%) of 75 patients discontinued canakinumab, and clinical remission was maintained for at least 24 weeks in all 25 of these patients. No new safety signals were identified. CONCLUSION: Reduction of canakinumab exposure may be feasible in patients who have achieved clinical remission of systemic JIA, but consistent interleukin-1 inhibition appears necessary to maintain this response.

Published
2021

32. LB0004 EFFICACY AND SAFETY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS AND JUVENILE PSORIATIC ARTHRITIS: PRIMARY RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)

Author

Ruperto, N., primary, Foeldvari, I., additional, Alexeeva, E., additional, Aktay Ayaz, N., additional, Calvo, I., additional, Kasapcopur, O., additional, Chasnyk, V., additional, Hufnagel, M., additional, Żuber, Z., additional, Schulert, G., additional, Ozen, S., additional, Popov, A., additional, Ramanan, A., additional, Scott, C., additional, Sözeri, B., additional, Zholobova, E., additional, Zhu, X., additional, Whelan, S., additional, Pricop, L., additional, Ravelli, A., additional, Martini, A., additional, Lovell, D. J., additional, and Brunner, H., additional

Published
2021
Full Text
View/download PDF

33. POS1310 CANAKINUMAB IS A RESCUE TREATMENT FOR MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS: SINGLE CENTER EXPERIENCE

Author

Kostik, M., primary, Isupova, E., additional, Chikova, I., additional, Likhacheva, T., additional, Masalova, V., additional, Snegireva, L., additional, Dubko, M., additional, Gaidar, E., additional, Kaneva, M., additional, Kornishina, T., additional, Kalashnikova, O., additional, and Chasnyk, V., additional

Published
2021
Full Text
View/download PDF

35. POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE

Author

Kostik, M., primary, Raupov, R., additional, Suspitsin, E., additional, Isupova, E., additional, Gabrusskaya, T., additional, Dubko, M., additional, Snegireva, L., additional, Masalova, V., additional, Ermachenkova, T., additional, Sorokina, L., additional, Likhacheva, T., additional, Kaneva, M., additional, Gaidar, E., additional, Kalashnikova, O., additional, and Chasnyk, V., additional

Published
2021
Full Text
View/download PDF

41. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

Author

Brunner, Hermine, Ruperto, N., Tzaribachev, N., Horneff, G., Wouters, C., Panaviene, V., Chasnyk, V., Abud-Mendoza, C., Cuttica, R., Reiff, A., Maldonado-Velázquez, M., Rubio-Perez, N., Alexeeva, Ekaterina, Joos, R., Keltsev, V., Nasonov, E., Kingsbury, D., Bandeira, M., Silverman, E., Weller-Heinemann, F., van Royen-Kerkhof, A., Mendelsohn, Alan, Kim, Lilianne, Lovell, D., and Martini, A.

Published
2014
Full Text
View/download PDF

44. OP0291 TOFACITINIB FOR THE TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: RESULTS OF A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY

Author

Ruperto, N., primary, Synoverska, O., additional, Ting, T., additional, Abud-Mendoza, C., additional, Spindler, A., additional, Vyzhga, Y., additional, Marzan, K., additional, Keltsev, V., additional, Tirosh, I., additional, Imundo, L., additional, Jerath, R., additional, Kingsbury, D., additional, Sözeri, B., additional, Vora, S., additional, Prahalad, S., additional, Zholobova, E., additional, Butbul Aviel, Y., additional, Chasnyk, V., additional, Lerman, M., additional, Nanda, K., additional, Schmeling, H., additional, Tory, H., additional, Uziel, Y., additional, Viola, D. O., additional, Posner, H., additional, Kanik, K., additional, Wouters, A., additional, Chang, C., additional, Zhang, R., additional, Lazariciu, I., additional, Hsu, M. A., additional, Suehiro, R., additional, Martini, A., additional, Lovell, D. J., additional, and Brunner, H., additional

Published
2020
Full Text
View/download PDF

46. DYNAMICS OF THE INFANT MORTALITY RATE IN THE REPUBLIC OF SAKHA (YAKUTIA)

Author

Ivanov, D. O., primary, Orel, Vasily I., additional, Chasnyk, V. G., additional, Kim, A. V., additional, Okhlopkov, M. E., additional, Grigorieva, A. N., additional, Burtseva, T. E., additional, Orel, O. V., additional, Libova, E. B., additional, Buldakova, T. I., additional, Sharafutdinova, L. L., additional, Nosireva, O. M., additional, Roslova, Z. A., additional, and Gureva, N. A., additional

Published
2019
Full Text
View/download PDF

47. Structure and Current-Voltage Characteristics of Islet Gold Films on High-Heat Conducting Pressureless Sintered AlN Ceramics

Author

Fesenko, I. P., primary, Viduta, L. B., additional, Chasnyk, V. I., additional, Nechytailo, V. B., additional, Butenko, D. V., additional, Tkach, V. M., additional, Turkevich, V. Z., additional, Marchenko, O. A., additional, Zelenska, I. I., additional, Kaidash, O. M., additional, Serbenyuk, T. B., additional, Belyaeva, T. M., additional, Kuz’menko, E. F., additional, and Tomchuk, P. M., additional

Published
2018
Full Text
View/download PDF

48. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Author

Ravelli, A, Minoia, F, Davì, S, Horne, A, Bovis, F, Pistorio, A, Aricò, M, Avcin, T, Behrens, Em, De Benedetti, F, Filipovic, A, Grom, Aa, Henter, J-i, Ilowite, Nte, Jordan, Mb, Khubchandani, R, Kitoh, T, Lehmberg, K, Lovell, Dj, Miettunen, P, Nichols, Ke, Ozen, S, Schmid, Jp, Ramanan, Av, Russo, R, Schneider, R, Sterba, G, Uziel, Y, Wallace, C, Wouters, C, Wulffraat, N, Demirkaya, E, Brunner, Hi, Martini, A, Ruperto, N, Cron, Rq, Angioloni, S, Pallotti, C, Pesce, M, Rinaldi, M, Villa, L, Abinun, M, Aggarwal, A, Akikusa, J, Al-mayouf, Sm, Alessio, M, Anton, J, Apaz, Mt, Astigarraga, I, Ayaz, Na, Barone, P, Bica, B, Bolt, I, Breda, L, Chasnyk, V, Cimaz, R, Corona, F, Cuttica, R, D'Angelo, G, Davidsone, Z, De Cunto, C, De Inocencio, J, Eisenstein, E, Enciso, S, Espada, G, Fischbach, M, Frosch, M, Gallizzi, R, Gamir, Ml, Gao, Y-j, Griffin, T, Hashad, S, Hennon, T, Horneff, G, Huasong, Z, Huber, A, Insalaco, A, Ioseliani, M, Jelusic-drazic, M, Jeng, M, Kapovic, A, Kasapcopur, O, Kone-paut, I, De Oliveira Skf, Lattanzi, B, Lepore, L, Li, C, Lipton, Jm, Magni-manzoni, S, Maritsi, D, Mccurdy, D, Merino, R, Mulaosmanovic, V, Nielsen, S, Pal, P, Prahalad, S, Rigante, Donato, Rumba-rozenfelde, I, Magalhaes, Cs, Sanner, H, Sawhney, S, Sewairi, Wm, Shakoory, B, Shenoi, S, Clovis, As, Stanevicha, V, Stine, Kc, Susic, G, Sztajnbok, F, Takei, S, Tezer, H, Trauzeddel, R, Tsitsami, E, Unsal, E, Vougiouka, O, Weaver, Lk, Weiss, J, Weitzman, S, On Behalf Of The Pediatric Rheumatology International Trials Organization, Zletni M., The Childhood Arthritis & Rheumatology Research Alliance, The Pediatric Rheumatology Collaborative Study Group And The Histiocyte Society, Ravelli, A., Minoia, F., Davi, S., Horne, A., Bovis, F., Pistorio, A., Arico, M., Avcin, T., Behrens, E. M., De Benedetti, F., Filipovic, A., Grom, A. A., Henter, J. -I., Ilowite, N. T., Jordan, M. B., Khubchandani, R., Kitoh, T., Lehmberg, K., Lovell, D. J., Miettunen, P., Nichols, K. E., Ozen, S., Schmid, J. P., Ramanan, A. V., Russo, R., Schneider, R., Sterba, G., Uziel, Y., Wallace, C., Wouters, C., Wulffraat, N., Demirkaya, E., Brunner, H. I., Martini, A., Ruperto, N., Cron, R. Q., Angioloni, S., Pallotti, C., Pesce, M., Rinaldi, M., Villa, L., Abinun, M., Aggarwal, A., Akikusa, J., Al-Mayouf, S. M., Alessio, M., Anton, J., Apaz, M. T., Astigarraga, I., Ayaz, N. A., Barone, P., Bica, B., Bolt, I., Breda, L., Chasnyk, V., Cimaz, R., Corona, F., Cuttica, R., D'Angelo, G., Davidsone, Z., De Cunto, C., De Inocencio, J., Eisenstein, E., Enciso, S., Espada, G., Fischbach, M., Frosch, M., Gallizzi, R., Gamir, M. L., Gao, Y. -J., Griffin, T., Hashad, S., Hennon, T., Horneff, G., Huasong, Z., Huber, A., Insalaco, A., Ioseliani, M., Jelusic-Drazic, M., Jeng, M., Kapovic, A., Kasapcopur, O., Kone-Paut, I., De Oliveira, S. K. F., Lattanzi, B., Lepore, L., Li, C., Lipton, J. M., Magni-Manzoni, S., Maritsi, D., Mccurdy, D., Merino, R., Mulaosmanovic, V., Nielsen, S., Pal, P., Prahalad, S., Rigante, D., Rumba-Rozenfelde, I., Magalhaes, C. S., Sanner, H., Sawhney, S., Sewairi, W. M., Shakoory, B., Shenoi, S., Clovis, A. S., Stanevicha, V., Stine, K. C., Susic, G., Sztajnbok, F., Takei, S., Tezer, H., Trauzeddel, R., Tsitsami, E., Unsal, E., Vougiouka, O., Weaver, L. K., Weiss, J., Weitzman, S., Zletni, M., and Çocuk Sağlığı ve Hastalıkları

Subjects
medicine.medical_specialty, systemic juvenile idiopathic arthritis, Epidemiology, Immunology, Arthritis, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, medicine, Journal Article, Immunology and Allergy, 030212 general & internal medicine, Juvenile Idiopathic Arthritis, Prospective cohort study, 030203 arthritis & rheumatology, medicine.diagnostic_test, business.industry, Paediatric Rheumatology, medicine.disease, Outcomes research, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Macrophage activation syndrome, Erythrocyte sedimentation rate, Absolute neutrophil count, sense organs, business
Abstract

OBJECTIVE: To identify which laboratory tests that change over time are most valuable for the timely diagnosis of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA).METHODS: A multistep process, based on a combination of expert consensus and analysis of real patient data, was conducted. A panel of experts was first asked to evaluate 115 profiles of patients with MAS, which included the values of laboratory tests at the pre-MAS visit and at MAS onset, and the change in values between the two time points. The experts were asked to choose the 5 laboratory tests in which change was most important for the diagnosis of MAS and to rank the 5 selected tests in order of importance. The relevance of change in laboratory parameters was further discussed and ranked by the same experts at a consensus conference.RESULTS: Platelet count was the most frequently selected test, followed by ferritin level, aspartate aminotransferase (AST), white cell count, neutrophil count, and fibrinogen and erythrocyte sedimentation rate. Ferritin was most frequently assigned the highest score. At the end of the process, platelet count, ferritin level and AST were the laboratory tests in which the experts found change over time to be most important.CONCLUSIONS: We identified the laboratory tests in which change over time is most valuable for the early diagnosis of MAS in sJIA. The dynamics of laboratory values during the course of MAS should be further scrutinised in a prospective study in order to establish the optimal cut-off values for their variation.

Published
2016

49. A Study of the Thermal Conductivity, Electrical Resistivity, and Microwave Absorption of Pressureless Sintered AlN–Y2O3–Mo and AlN–Y2O3–TiN Composites.

Author

Chasnyk, V. I., Chasnyk, D. V., Fesenko, I. P., and Kaidash, O. M.

Abstract

Compositions of AlN–Y2O3–Mo and AlN–Y2O3–TiN composite materials with high thermal conductivity have been selected for bulk absorbers of microwave energy in delay systems. The thermal conductivity, electrical resistivity, and electromagnetic absorption of pressureless sintered AlN-based composites with different volume concentrations of conducting Mo and TiN particles are determined. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results